Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain's FTSE edges down ahead of growth data, RBS soars

Fri, 25th Jul 2014 08:19

* FTSE 100 down 0.1 pct, investor sentiment muted onearnings

* Q2 GDP data in focus after IMF upgrades

* RBS jumps 14 pct, biggest one-day gain in four years

* BSkyB deal hits shares, Burberry weaker on LVMH

LONDON, July 25 (Reuters) - UK shares edged lower in earlytrading on Friday, ahead of second quarter GDP data, asinvestors digested a raft of corporate results and Royal Bank ofScotland enjoyed an unexpected pop from earnings.

Investor sentiment was muted across Europe, held back bydisappointing earnings on both sides of the Atlantic and by athird consecutive monthly fall in the widely followed German Ifosurvey of business sentiment.

Merger activity also dominated early trading, with BSkyB agreeing to pay 4.9 billion pounds ($8.3 billion) incash to buy Rupert Murdoch's pay-TV assets in Germany and Italy.Construction companies Balfour Beatty and Carillion rallied after confirming merger talks.

The FTSE 100 index was down 0.1 percent, slightly betterthan Germany's DAX and the French CAC 40, whilethe pan-European FTSEurofirst 300 was down 0.2 percent.

A preliminary reading of second quarter British grossdomestic product was in focus after the International MonetaryFund this week upgraded its forecasts for the UK economy.

"Today's first iteration of Q2 GDP could well be a goodindicator of how well the UK economy is shaping up for the restof the year," CMC Markets analyst Michael Hewson said.

Shares of RBS soared 14.5 percent, their biggest intradaygain in at least four years, after the lender released earningsa week early that were much better than expected.

Network operator Vodafone was also up 2.2 percentafter saying its performance had begun to stabilise in severalEuropean markets even as a slowdown in Spain and South Africaled to another heavy drop in its key revenue measure.

Meanwhile, BSkyB fell 2.4 percent, the worst performer onthe FTSE 100, with traders citing the placement of sharesrepresenting around 10 percent of the company's capital to helppay for its announced asset purchases.

Burberry fell 1.9 percent after French luxury goodsgroup LVMH posted below-forecast second quarter salesand profits, hit by a drop in demand from China.

Another heavy faller was drugmaker GlaxoSmithKline,down 1.8 percent. The company faces new allegations ofcorruption, this time in Syria, where the drugmaker and itsdistributor have been accused of paying bribes to securebusiness, according to a whistleblower's email.

Publisher Pearson posted a 41 percent slump infirst-half profit, reflecting increased restructuring charges,currency movements and phasing in of revenues into the secondhalf, though an increased dividend helped the stock tradehigher. (Reporting by Lionel Laurent; Editing by Catherine Evans)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.